欧林生物1月29日获融资买入430.21万元，融资余额3.53亿元

Group 1 - The core viewpoint of the news is that Oulin Bio experienced a decline in stock price and significant changes in financing activities on January 29, with a net financing outflow of 842.01 million yuan [1] - On January 29, Oulin Bio's financing buy-in amounted to 4.30 million yuan, while the financing repayment was 12.72 million yuan, resulting in a total financing balance of 353 million yuan, which represents 3.56% of its market capitalization [1] - The company has a high financing balance, exceeding the 80th percentile of the past year, indicating elevated financing activity [1] Group 2 - As of September 30, Oulin Bio had 10,200 shareholders, an increase of 56.42% from the previous period, while the average number of circulating shares per person decreased by 36.07% to 39,746 shares [2] - For the period from January to September 2025, Oulin Bio reported revenue of 507 million yuan, a year-on-year increase of 31.11%, and a net profit attributable to shareholders of 47.48 million yuan, reflecting a substantial growth of 1079.36% [2] - Since its A-share listing, Oulin Bio has distributed a total of 15.43 million yuan in dividends [3] Group 3 - Among the top ten circulating shareholders as of September 30, 2025, the fifth largest is XQH Run Mixed A, holding 15.44 million shares, with no change from the previous period [3] - XQH Yi Mixed A ranks seventh with 8.92 million shares, also unchanged, while XQH Commercial Model Mixed (LOF) A is a new entrant in the top ten, holding 4.64 million shares [3]